Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2019

06.02.2019 | Epidemiology

Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women

verfasst von: Tess O’Meara, Anton Safonov, David Casadevall, Tao Qing, Andrea Silber, Brigid Killelea, Christos Hatzis, Lajos Pusztai

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

African-American (AA) patients with triple-negative breast cancer (TNBC) are less likely to achieve pathologic complete response from neoadjuvant chemotherapy and have poorer prognosis than Caucasian patients with TNBC, suggesting potential biological differences by race. Immune infiltration is the most consistent predictive marker for chemotherapy response and improved prognosis in TNBC. In this study, we test the hypothesis that the immune microenvironment differs between AA and Caucasian patients.

Methods

RNA-seq expression data were obtained from The Cancer Genome Atlas (TCGA) database for 162 AA and 697 Caucasian breast cancers. Estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-positive, and TNBC subtypes were included in the analyses. Tumor infiltrating lymphocyte (TIL) counts, immunomodulatory scores, and molecular subtypes were obtained from prior publications for a subset of the TNBC cases. Differences in immune cell distributions and immune functions, measured through gene expression and TIL counts, as well as neoantigen, somatic mutation, amplification, and deletion loads, were compared by race and tumor subtype.

Results

Immune metagene analysis demonstrated marginal immune attenuation in AA TNBC relative to Caucasian TNBC that did not reach statistical significance. The distributions of immune cell populations, lymphocyte infiltration, molecular subtypes, and genomic aberrations between AA and Caucasian subtypes were also not significantly different. The MHC1 metagene demonstrated increased expression in AA ER-positive cancers relative to Caucasian ER-positive cancers.

Conclusions

This study suggests that the immunological differences between AA and Caucasian breast cancers represented by TCGA data are subtle, if they exist at all. We observed no consistent racial differences in immune gene expression or TIL counts in TNBC by race. However, this study cannot rule out small differences in immune cell subtype distribution and activity status that may not be apparent in bulk RNA analysis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat DeSantis C et al. (2014) Breast cancer statistics, 2013. CA: A Cancer J Clin 64(1):52–62 DeSantis C et al. (2014) Breast cancer statistics, 2013. CA: A Cancer J Clin 64(1):52–62
2.
Zurück zum Zitat DeSantis CE et al (2016) Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 66(1):31–42CrossRefPubMed DeSantis CE et al (2016) Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 66(1):31–42CrossRefPubMed
3.
Zurück zum Zitat Stark A et al (2010) African ancestry and higher prevalence of triple-negative breast cancer. Cancer 116(21):4926–4932CrossRefPubMed Stark A et al (2010) African ancestry and higher prevalence of triple-negative breast cancer. Cancer 116(21):4926–4932CrossRefPubMed
4.
Zurück zum Zitat Eric C, Dietze CS, Miranda-Carboni G, Ruth O’Regan, Seewaldt VL (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15:248–254CrossRef Eric C, Dietze CS, Miranda-Carboni G, Ruth O’Regan, Seewaldt VL (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15:248–254CrossRef
5.
Zurück zum Zitat Shinde SS et al (2010) Higher parity and shorter breastfeeding duration. Cancer 116(21):4933–4943CrossRefPubMed Shinde SS et al (2010) Higher parity and shorter breastfeeding duration. Cancer 116(21):4933–4943CrossRefPubMed
6.
Zurück zum Zitat Lawrence TS, Rosenberg SA (2010) L, Definition of triple-negative breast cancer and relationship to basal-like molecular subtype. In: VT DeVita Jr (eds) PPO updates: principles and practice of oncology. Lippincott Williams & Wilkins, New York, pp 1–6 Lawrence TS, Rosenberg SA (2010) L, Definition of triple-negative breast cancer and relationship to basal-like molecular subtype. In: VT DeVita Jr (eds) PPO updates: principles and practice of oncology. Lippincott Williams & Wilkins, New York, pp 1–6
7.
Zurück zum Zitat Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, Mills GB, Laird PW, Shriver CD, Perou CM, Olopade OI (2017) Comparison of breast cancer molecular features and survival by African and European Ancestry in the cancer genome atlas. JAMA Oncol 3(12):1654–1662CrossRefPubMedPubMedCentral Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, Mills GB, Laird PW, Shriver CD, Perou CM, Olopade OI (2017) Comparison of breast cancer molecular features and survival by African and European Ancestry in the cancer genome atlas. JAMA Oncol 3(12):1654–1662CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Killelea BK et al (2015) Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the national cancer data base. J Clin Oncol 33(36):4267–4276CrossRefPubMed Killelea BK et al (2015) Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the national cancer data base. J Clin Oncol 33(36):4267–4276CrossRefPubMed
9.
Zurück zum Zitat Karn T et al (2015) The influence of host factors on the prognosis of breast cancer: stroma and immune cell components as cancer biomarkers. Curr Cancer Drug Targets 15(8):652–664CrossRefPubMed Karn T et al (2015) The influence of host factors on the prognosis of breast cancer: stroma and immune cell components as cancer biomarkers. Curr Cancer Drug Targets 15(8):652–664CrossRefPubMed
10.
Zurück zum Zitat Bianchini G et al (2010) Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor–positive and –negative cancers. J Clin Oncol 28(28):4316–4323CrossRefPubMed Bianchini G et al (2010) Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor–positive and –negative cancers. J Clin Oncol 28(28):4316–4323CrossRefPubMed
11.
Zurück zum Zitat Adams S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959–2966CrossRefPubMedPubMedCentral Adams S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959–2966CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Wimberly H et al (2015) PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 3(4):326–332CrossRefPubMed Wimberly H et al (2015) PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 3(4):326–332CrossRefPubMed
13.
Zurück zum Zitat Efremova M, Finotello F, Rieder D, Trajanoski Z (2017) Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol 8:1679CrossRefPubMedPubMedCentral Efremova M, Finotello F, Rieder D, Trajanoski Z (2017) Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol 8:1679CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Safonov A et al (2017) Immune gene expression is associated with genomic aberrations in breast cancer. Can Res 77(12):3317–3324CrossRef Safonov A et al (2017) Immune gene expression is associated with genomic aberrations in breast cancer. Can Res 77(12):3317–3324CrossRef
15.
Zurück zum Zitat Karn T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L (2017) Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol 3(12):1707–1711CrossRefPubMedPubMedCentral Karn T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L (2017) Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol 3(12):1707–1711CrossRefPubMedPubMedCentral
16.
17.
Zurück zum Zitat McGranahan N et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463CrossRefPubMedPubMedCentral McGranahan N et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Rody A et al (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11(2):R15CrossRefPubMedPubMedCentral Rody A et al (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11(2):R15CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Callari M et al (2016) Subtype-specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer. Clin Cancer Res 22(2):337–345CrossRefPubMed Callari M et al (2016) Subtype-specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer. Clin Cancer Res 22(2):337–345CrossRefPubMed
21.
Zurück zum Zitat Denkert C et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105–113CrossRefPubMed Denkert C et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105–113CrossRefPubMed
22.
Zurück zum Zitat Esteva FJ et al (2007) CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res 9(6):R87CrossRefPubMedPubMedCentral Esteva FJ et al (2007) CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res 9(6):R87CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Lennerz V et al (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102(44):16013–16018CrossRefPubMedPubMedCentral Lennerz V et al (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102(44):16013–16018CrossRefPubMedPubMedCentral
24.
25.
26.
Zurück zum Zitat Hsiao TH et al (2013) Identification of genomic functional hotspots with copy number alteration in liver cancer. EURASIP J Bioinform Syst Biol 2013(1):14CrossRefPubMedPubMedCentral Hsiao TH et al (2013) Identification of genomic functional hotspots with copy number alteration in liver cancer. EURASIP J Bioinform Syst Biol 2013(1):14CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48–61CrossRefPubMedPubMedCentral Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48–61CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Peter Kang S, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK (2017) IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig 127(8):2930–2940CrossRefPubMedPubMedCentral Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Peter Kang S, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK (2017) IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig 127(8):2930–2940CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Ritchie ME et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47–e47CrossRefPubMedPubMedCentral Ritchie ME et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47–e47CrossRefPubMedPubMedCentral
34.
35.
Zurück zum Zitat Lehmann BD et al (2016) Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 11(6):e0157368CrossRefPubMedPubMedCentral Lehmann BD et al (2016) Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 11(6):e0157368CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Loi S et al (2016) RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 22(6):1499CrossRefPubMed Loi S et al (2016) RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 22(6):1499CrossRefPubMed
37.
Zurück zum Zitat Luen S et al (2016) The genomic landscape of breast cancer and its interaction with host immunity. The Breast 29:241–250CrossRefPubMed Luen S et al (2016) The genomic landscape of breast cancer and its interaction with host immunity. The Breast 29:241–250CrossRefPubMed
38.
Zurück zum Zitat Edmund A.Mroza JWR (2013) MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol 49(3):211–215CrossRef Edmund A.Mroza JWR (2013) MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol 49(3):211–215CrossRef
39.
Zurück zum Zitat Chowell D et al. (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359(6375):582–587CrossRefPubMed Chowell D et al. (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359(6375):582–587CrossRefPubMed
40.
Zurück zum Zitat Cao K et al (2001) Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 62(9):1009–1030CrossRefPubMed Cao K et al (2001) Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 62(9):1009–1030CrossRefPubMed
41.
Zurück zum Zitat Pitt JJ et al (2018) Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun 9(1):4181CrossRefPubMedPubMedCentral Pitt JJ et al (2018) Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun 9(1):4181CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Keenan T et al (2015) Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence. J Clin Oncol 33(31):3621–3627CrossRefPubMedPubMedCentral Keenan T et al (2015) Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence. J Clin Oncol 33(31):3621–3627CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Martin DN et al (2009) Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS ONE 4(2):e4531CrossRefPubMedPubMedCentral Martin DN et al (2009) Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS ONE 4(2):e4531CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Elkhanany A, Katsuta E, Takabe K (2018) Racial disparity in breast cancer immune microenvironment. J Clin Oncol 36(15_suppl):1081–1081CrossRef Elkhanany A, Katsuta E, Takabe K (2018) Racial disparity in breast cancer immune microenvironment. J Clin Oncol 36(15_suppl):1081–1081CrossRef
46.
Zurück zum Zitat Mu J et al (2014) Regulation of MHC class I expression by Foxp3 and its effect on regulatory T cell function. J Immunol 192(6):2892CrossRefPubMed Mu J et al (2014) Regulation of MHC class I expression by Foxp3 and its effect on regulatory T cell function. J Immunol 192(6):2892CrossRefPubMed
Metadaten
Titel
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women
verfasst von
Tess O’Meara
Anton Safonov
David Casadevall
Tao Qing
Andrea Silber
Brigid Killelea
Christos Hatzis
Lajos Pusztai
Publikationsdatum
06.02.2019
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05156-5

Weitere Artikel der Ausgabe 1/2019

Breast Cancer Research and Treatment 1/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.